Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis

Hayashi,Daichi; Shirai,Toshiharu; Terauchi,Ryu; Tsuchida,Shinji; Mizoshiri,Naoki; Mori,Yuki; Arai,Yuji; Mazda,Osam; Kubo,Toshikazu

doi:10.3892/ol.2020.11405

Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis

Authors:
- Daichi Hayashi
- Toshiharu Shirai
- Ryu Terauchi
- Shinji Tsuchida
- Naoki Mizoshiri
- Yuki Mori
- Yuji Arai
- Osam Mazda
- Toshikazu Kubo
View Affiliations

Affiliations: Department of Orthopedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan, Department of Sports and Parasports Medicine, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan, Department of Immunology, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Published online on: February 17, 2020 https://doi.org/10.3892/ol.2020.11405
Pages: 2963-2970

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibrosarcoma is a soft tissue sarcoma that is classified as a rare cancer. Therefore, no standard anti‑tumor drug therapy has been established for fibrosarcoma. Although pristimerin (PM) has been reported to exert an anti‑tumor effect on various types of cancer, no studies have examined the therapeutic effect of PM on soft tissue sarcoma. The purpose of the current study was to investigate the anti‑tumor effect of PM on human fibrosarcoma cells (HT1080). The present study examined the cell viability, IC50 values and ability to induce apoptosis of PM in HT1080 and normal human dermal fibroblast (aHDF) cells. The effect of PM on the following signaling pathways associated with cell proliferation was also evaluated: AKT and mitogen‑activated protein kinase (MAPK). Using mice subcutaneously transplanted with fibrosarcoma cells, the effect of PM treatment was investigated on tumor growth inhibition, body weight and liver and renal function. The results revealed that PM administration reduced cell viability and induced apoptosis in a dose‑dependent matter. In HT1080 cells, the IC50 value of PM was 0.16 µM at 24 h and 0.13 µM at 48 h. PM treatment also decreased the levels of phosphorylated AKT, mTOR, NF‑κB and phosphorylated ERK in a dose‑dependent manner. In the PM injection group, the increase in tumor volume was significantly reduced and the effect on weight loss and liver and renal function were revealed to be insignificant. PM exerted little effect on normal human dermal fibroblasts and was highly effective against human fibrosarcoma cells. The results indicated that PM may be used as a potential therapeutic agent against fibrosarcoma.

View Figures

View References

1	Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, et al: Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma. Cancer Sci. 109:3962–3970. 2018. View Article : Google Scholar : PubMed/NCBI
2	Jain S, Xu R, Prieto VG and Lee P: Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol. 3:416–428. 2010.PubMed/NCBI
3	Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A and Ghert M: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 113:573–581. 2008. View Article : Google Scholar : PubMed/NCBI
4	Eilber FR, Giuliano AE, Huth JF and Morton DL: A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. Am J Clin Oncol. 11:39–45. 1988. View Article : Google Scholar : PubMed/NCBI
5	Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 23:311–321. 1987. View Article : Google Scholar : PubMed/NCBI
6	Mytilinaiou M, Nikitovic D, Berdiaki A, Papoutsidakis A, Papachristou DJ, Tsatsakis A and Tzanakakis GN: IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis. Exp Cell Res. 361:9–18. 2017. View Article : Google Scholar : PubMed/NCBI
7	Ratan R and Patel SR: Chemotherapy for soft tissue sarcoma. Cancer. 122:2952–2960. 2016. View Article : Google Scholar : PubMed/NCBI
8	Sun Y, Gao LL, Tang MY, Feng BM, Pei YH and Yasukawa K: Triterpenoids from Euphorbia maculata and their anti-inflammatory effects. Molecules. 23:E21122018. View Article : Google Scholar : PubMed/NCBI
9	Patlolla JM and Rao CV: Triterpenoids for cancer prevention and treatment: Current status and future prospects. Curr Pharm Biotechnol. 13:147–155. 2012. View Article : Google Scholar : PubMed/NCBI
10	Akihisa T, Tokuda H, Ichiishi E, Mukainaka T, Toriumi M, Ukiya M, Yasukawa K and Nishino H: Anti-tumor promoting effects of multiflorane-type triterpenoids and cytotoxic activity of karounidiol against human cancer cell lines. Cancer Lett. 173:9–14. 2001. View Article : Google Scholar : PubMed/NCBI
11	Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y and Suzuki T: Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol. 107:249–253. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sassa H, Kogure K, Takaishi Y and Terada H: Structural basis of potent antiperoxidation activity of the triterpene celastrol in mitochondria: Effect of negative membrane surface charge on lipid peroxidation. Free Radic Biol Med. 17:201–207. 1994. View Article : Google Scholar : PubMed/NCBI
13	Dirsch VM, Kiemer AK, Wagner H and Vollmar AM: The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol. 336:211–217. 1997. View Article : Google Scholar : PubMed/NCBI
14	Lee JS, Yoon IS, Lee MS, Cha EY, Thuong PT, Diep TT and Kim JR: Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol Pharm Bull. 36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X and Dou QP: Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem. 103:234–244. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG: The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen speciesmediated mitochondrial dysfunction. Oncol Lett. 5:242–248. 2013. View Article : Google Scholar : PubMed/NCBI
17	Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD, Park KH, Hyun JW, Lee YS, Lee JS, Yoon MY and Lee SJ: Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol. 76:734–744. 2009. View Article : Google Scholar : PubMed/NCBI
18	Costa PM, Ferreira PM, Bolzani Vda S, Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de Moraes MO, Costa-Lotufo LV, Montenegro RC and Pessoa C: Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro. 22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
19	Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S and Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer. 94:3225–3229. 2002. View Article : Google Scholar : PubMed/NCBI
20	Keller F, Wilms H, Schultze G, Offerman G and Molzahn M: Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol. 19:201–205. 1983.PubMed/NCBI
21	Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR and Wu YC: Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
22	Mori Y, Shirai T, Terauchi R, Tsuchida S, Mizoshiri N, Hayashi D, Arai Y, Kishida T, Mazda O and Kubo T: Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo. Onco Targets Ther. 10:5703–5710. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
24	Wyllie AH, Kerr JF and Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol. 68:251–306. 1980. View Article : Google Scholar : PubMed/NCBI
25	Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan J: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010. View Article : Google Scholar : PubMed/NCBI
26	Yousef BA, Hassan HM, Guerram M, Hamdi AM, Wang B, Zhang LY and Jiang ZZ: Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells. Biomed Pharmacother. 79:112–119. 2016. View Article : Google Scholar : PubMed/NCBI
27	Xie G, Yu X, Liang H, Chen J, Tang X, Wu S and Liao C: Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling. Oncol Lett. 11:3111–3116. 2016. View Article : Google Scholar : PubMed/NCBI
28	Murgia M, Pizzo P, Sandoná D, Zanovello P, Rizzuto R and Di Virgilio F: Mitochondrial DNA is not fragmented during apoptosis. J Biol Chem. 267:10939–10941. 1992.PubMed/NCBI
29	Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K and Harada M: Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget. 5:11399–11412. 2014. View Article : Google Scholar : PubMed/NCBI
30	Polivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
31	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
32	Brown JS and Banerji U: Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 172:101–115. 2017. View Article : Google Scholar : PubMed/NCBI
33	Burris HA III: Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
34	Mu X, Shi W, Sun L, Li H, Jiang Z and Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules. 17:6854–6868. 2012. View Article : Google Scholar : PubMed/NCBI
35	Brasier AR: The NF-kappaB regulatory network. Cardiovasc Toxicol. 6:111–130. 2006. View Article : Google Scholar : PubMed/NCBI
36	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
37	Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, Tyler KL and Dermody TS: Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol. 74:2981–2989. 2000. View Article : Google Scholar : PubMed/NCBI
38	Hu G, Wang X, Han Y and Wang P: Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-κB dependent apoptosis. EXCLI J. 17:1157–1166. 2018.PubMed/NCBI
39	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
40	Potthoff RF and George SL: Flexible phase I clinical trials: Allowing for nonbinary toxicity response and removal of other common limitations. Stat Biopharm Res. 1:213–228. 2009. View Article : Google Scholar : PubMed/NCBI
41	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
42	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
43	Cevatemre B, Erkısa M, Aztopal N, Karakas D, Alper P, Tsimplouli C, Sereti E, Dimas K, Armutak EII, Gurevin EG, et al: A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer. Pharmacol Res Mar. 129:500–514. 2018. View Article : Google Scholar
44	Ravasco P, Monteiro-Grillo I, Vidal PM and Camilo ME: Cancer: Disease and nutrition are key determinants of patients' quality of life. Support Care Cancer. 12:246–252. 2004. View Article : Google Scholar : PubMed/NCBI